In vitro susceptibility pattern of Acinetobacter species to commonly used cephalosporins, quinolones, and aminoglycosides

Indian Journal of Medical Microbiology

Volumn 22, Issue 2, 2004, Pages 97-103

  Prashanth, K ^a,b   Badrinath, S ^a  

^a JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

^b CENTRE FOR DNA FINGERPRINTING AND DIAGNOSTICS   (India)

Author keywords

A.baumannii; Biotyping; Multidrug resistance

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; CARBON; CEFAZOLIN; CEFOTAXIME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; DNA; GENTAMICIN; NETILMICIN; NORFLOXACIN; OFLOXACIN; PIPERACILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ACINETOBACTER; ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BIOTYPE; CARBON FIXATION; CONTROLLED STUDY; DIFFUSION; DRUG USE; GENUS; HOSPITAL INFECTION; IN VITRO STUDY; MEDICAL DECISION MAKING; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PHENOTYPE; PRACTICE GUIDELINE; SPECIES DIFFERENCE;

EID: 2442441207     PISSN: 02550857     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Bergogne- Berezin E, Towner KJ. Acinetobacter spp. as Nosocomial Pathogens; Microbiological, Clinical and Epidemiological features. Clin Microbiol Rev 1996;9:148-165.
2. Seifert H, Baginski R, Schulze A, Pulverer G. Antimicrobial susceptibility of Acinetobacter species. Antimicrob Agents Chemother 1993;37:750-753.
3. Fagon JY, Chastre J, Domart Y, Trouillet JL, Pierre J, Darne C, Gilbert C. Nosocomial pneumonia in patients receiving continuous mechanical ventilation: prospective analysis of 52 episodes with use of a protected specimen brush and quantitative culture techniques. Am Rev Respir Dis 1989;139:887-894.
4. Seifert H, Strate A, Pulverer G. Nosocomial Bacteremia due to Acinetobacter baumannii: clinical features, epidemiology, and predictors of mortality. Medicine 1995;74(6):340-349.
5. Siegman-Igra Y, Bar-Yosef S, Gorea A, Avram J. Nosocomial Acinetobacter meningitis secondary to invasive procedures: Report of 25 cases and review. Clin Infect Dis 1993;17(5):843-849.
6. Ibrahim A, Gerner-Smidt P. Liesack W. Phylogenetic relationship of the twenty-one DNA groups of the genus Acinetobacter as revealed by 16S ribosomal DNA sequence analysis. Int J Syst Bacteriol 1997;47:837-841.
7. Gerner-Smidt P. Acinetobacter: Epidemiological and Taxonomic aspects. Acta Pathol Microbiol Immunol Scand 1994;102:(Supplement No 47):1-40.
8. Gerner-Smidt P, Tjernberg I, Ursing J. Reliability of phenotypic tests for identification of Acinetobacter species. J Clin Microbiol 1991;29:277-282.
9. Bouvet PJ, Grimont PA. Identification and biotyping of clinical isolates of Acinetobacter. Ann Inst Pasteur Microbiol 1987;138(5):569-578.
10. National Committee for Clinical Laboratory Standards: Performance standards for antimicrobial disk susceptibility tests. Approved standard M2-A6. NCCLS, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania, 1997.
11. National Committee for Clinical Laboratory Standards: Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically. Approved Standard M7-A4. NCCLS, Wayne, PA, 2000.
12. Beck-Sague CM, Jarvis WR, Brook JH, Culver DH, Potts A, Gay E, Shotts DW, Hill B, Anderson RL, Weinstein MP. Epidemic bacteremia due to Acinetobacter baumannii in five intensive care units. Am J Epidemiol 1990;132(4):723-733.
13. Kapil A, Gulati S, Goel V, Kumar L, Krishnan R, Kochupillai V. Outbreak of nosocomial Acinetobacter baumannii bacteremia in a high risk ward. Med Oncol 1998;15(4):270-274.
14. Iqbal Hossain M, Iqbal Kabir AK, Khan WA, Fuchs GJ. Acinetobacter bacteraemia in patients with diarrhoeal disease. Epidemiol Infect 1998;120(2):139 -142.
15. Gulati S. Kapil A, Goel V, Das B, Dwivedhi SN, Mahapatra AK. Biotyping of Acinetobacter spp. isolated from Clinical Samples. Indian J Med Res 1999;110:160-163.
16. Chopade BA, Patwardhan RB, Dhakephalkar PK. Acinetobacter Infections in India: Genetic and Molecular Biological studies and some approaches to the problem. In: Tropical diseases - Molecular Biology and Control strategies. S. Kumar, AK Sen, GP Dutta & RN Sharma Eds. (CSIR, New Delhi) 1994:704-717.
17. Prashanth K, Badrinath S. Simplified phenotypic tests for identification of Acinetobacter spp. and their antimicrobial susceptibility status. J Med Microbiol 2000;49:773-778.
18. Bauernfeind A, Kljucar S, Jungwrith R. Overview of antibiotic resistance problems in Acinetobacter spp. In: Clinical importance and antibiotic resistance of Acinetobacter spp. Proceedings of a symposium held on 4-5 November 1996 Towner KJ, (ed) (Eilat, Israel). J Med Microbiol 1997;46:726-728.
19. Pandey A, Kapil A, Sood S, Goel V, Das B, Seth P. In vitro activities of ampicillin -sulbactum and amoxicillin-clavulanic acid against Acinetobacter baumannii. J Clin Microbiol 1998;36:3415-3416.
20. Patil JR, Chopade BA. Distribution and in vitro antimicrobial susceptibility of Acinetobacter species on the skin of healthy humans. Natl Med J India 2001;14(4):204-208.
21. Traub WH, Spohr M. Antimicrobial drug susceptibility of clinical isolates of Acinetobacter species (A.baumannii, A.haemolyticus, genospecies 3, and genospecies 6). Antimicrob Agents Chemother 1989;33:1617-1619.
22. Colombian Antimicrobial Resistance Study Group, Pfaller MA, Jones RN, Doern GV, Salazar JC. Multicenter evaluation of antimicrobial resistance to six broad-spectrum β-Lactams in Colombia: Comparison of data from 1997 and 1998 using the Etest method. Diagn Microbiol Infect Dis 1999;35:235-241.
23. Chang SC, Chen YC, Luh KT, Hsieh WC. In vitro activities of antimicrobial agents, alone and in combination, against Acinetobacter baumannii isolated from blood. Diagn Microbiol Infect Dis 1995;23(3):105-110.
24. Manikal VM, Landman D, Saurina G, Oydna E, Lal H, Quale J. Endemic carbapenem-resistant Acinetobacter species in Brooklyn, New York: citywide prevalence, inter-institutional spread, and relation to antibiotic usage. Clin Infect Dis 2000;31:101-106.
25. Turkish Antimicrobial Resistance Study Group, Pfaller MA, Korten V, Jones RN, Doern GV. Multicenter evaluation of the antimicrobial activity for seven broad-spectrum β-lactams in Turkey using the E-test method. Diagn Microbiol Infect Dis 1999;35(1):65-73.
26. Sofianou DC, Constandinidis TC, Yannacou M, Anastasiou H, Sofianos E. Analysis of risk factors for ventilator-associated pneumonia in a multidisciplinary intensive care unit. Eur J Clin Microbiol Infect Dis 2000;19:460-463.
27. Visalli MA, Jacobs MR, Moore TD, Renzi FA, Appelbaum PC. Activities of β-lactams against Acinetobacter genospecies as determined by agar dilution and E-test MIC methods. Antimicrob Agents Chemother 1997; 41:767-770.
28. Jones RN, Pfaller MA, Marshall SA, Hollis RJ, Wilke WW. Antimicrobial activity of 12 broad-spectrum agents tested against 270 nosocomial blood stream infection isolates caused by non-enteric gram-negative bacilli: Occurrence of resistance, molecular epidemiology, and screening for metallo-enzymes. Diagn Microbiol Infect Dis 1997;29(3):187-192.
29. Bello H, Gonzalez G, Dominguez M, Zemelman R, Garcia A, Mella S. Activity of selected betalactams, ciprofloxacin, and amikacin against different A. baumannii Biotypes from Chilean Hospitals. Diagn Microbiol Infect Dis 1997;28(4):183-186.